FDA Approval! A New Model for BioPharma... Dr. Sam Blackman, Founder & Head of Research and Development, Day One Biopharmaceuticals
This week on BioTech Nation, Dr. Sam Blackman, Founder and Head of Research and Development from Day One Biopharmaceuticals, shares the story behind the FDA approval of a groundbreaking drug for the most common childhood brain cancer. He talks about their innovative approach to starting a biopharma company and how it led to a newly FDA approved drug that treats the most common form of brain cancer in children
